| abstract |
Use of a nutritional composition that includes A sphingophospholipid, preferably sphingomyelin, and / or at least one sphingophospholipid degradation product selected from the group consisting of: ceramide, lysosphingophospholipid, sphingoid phosphate and free sphingid base, and B at least one non-digestible carbohydrate selected from the group consisting of fructo-oligosaccharides, galactooligosaccharides, gluco-oligosaccharides, arabino-oligosaccharides, mannan-oligosaccharides, xyl-oligosaccharides, fucooligosaccharides, arabinogalacto-oligosaccharides, glucomanne-oligosaccharides, oligosaccharides, oligosaccharides, oligosaccharides, oligosaccharides, oligosaccharides, oligosaccharides, oligosaccharides, oligosaccharides, oligosaccharides, oligosaccharides uronic acid for the manufacture of a composition to normalize the intestinal microbiota in a human subject with respect to the microbiota found in healthy thin subjects and / or in breastfed babies. |